Display options
Cite
Kim YA, Chang M, Park YJ, et al. Detection of Survivin and COX-2 in Thyroid Carcinoma: Anaplastic Carcinoma Shows Overexpression of Nuclear Survivin and Low COX-2 Expression. Korean J Pathol. 2012;46(1):55-60doi: 10.4132/KoreanJPathol.2012.46.1.55.
Kim, Y. A., Chang, M., Park, Y. J., & Kim, J. E. (2012). Detection of Survivin and COX-2 in Thyroid Carcinoma: Anaplastic Carcinoma Shows Overexpression of Nuclear Survivin and Low COX-2 Expression. Korean journal of pathology, 46(1), 55-60. https://doi.org/10.4132/KoreanJPathol.2012.46.1.55
Kim, Young A, et al. "Detection of Survivin and COX-2 in Thyroid Carcinoma: Anaplastic Carcinoma Shows Overexpression of Nuclear Survivin and Low COX-2 Expression." Korean journal of pathology vol. 46,1 (2012): 55-60. doi: https://doi.org/10.4132/KoreanJPathol.2012.46.1.55
Kim YA, Chang M, Park YJ, Kim JE. Detection of Survivin and COX-2 in Thyroid Carcinoma: Anaplastic Carcinoma Shows Overexpression of Nuclear Survivin and Low COX-2 Expression. Korean J Pathol. 2012 Feb;46(1):55-60. doi: 10.4132/KoreanJPathol.2012.46.1.55. Epub 2012 Feb 23. PMID: 23109979; PMCID: PMC3479706.
Copy Download .nbib Format: NLM
Share it on

Korean J Pathol. 2012 Feb;46(1):55-60. doi: 10.4132/KoreanJPathol.2012.46.1.55. Epub 2012 Feb 23.

Detection of Survivin and COX-2 in Thyroid Carcinoma: Anaplastic Carcinoma Shows Overexpression of Nuclear Survivin and Low COX-2 Expression.

Korean journal of pathology

Young A Kim, Meesoo Chang, Young Joo Park, Ji Eun Kim

Affiliations

  1. Department of Pathology, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.

PMID: 23109979 PMCID: PMC3479706 DOI: 10.4132/KoreanJPathol.2012.46.1.55

Abstract

BACKGROUND: Overexpression of survivin, a member of the inhibitors of apoptosis protein, has been reported in various carcinomas, and its interaction with cyclooxygenase 2 (COX-2) results in accelerated tumor progression. The purpose of this study is to investigate the immunohistochemical expression of survivin and COX-2 in benign and malignant thyroid tissues and to define its association with pathologic and clinical features.

METHODS: We examined expression of survivin and COX-2 by immunohistochemistry in 334 benign and malignant thyroid tissues and evaluated their clinical significance.

RESULTS: Expression of survivin showed an increase along the spectrum of thyroid carcinoma progression; rarely positive in adenomatous goiter, moderately positive in papillary carcinoma, and strongly positive in anaplastic carcinoma (AC). Papillary microcarcinoma revealed the highest COX-2 positivity and AC demonstrated the lowest positivity among thyroid cancers. Node negative carcinomas showed higher COX-2 expression than node positive tumors. Survivin expression did not correlate with COX-2.

CONCLUSIONS: Our findings suggest that survivin overexpression may be related to the pathogenesis of AC and can be a predictor of disease progression. COX-2 may be involved in the early phase of thyroid carcinoma.

Keywords: BIRC5 protein, human; Cyclooxygenase 2; Thyroid cancer, anaplastic; Thyroid gland

References

  1. J Biol Chem. 1998 May 1;273(18):11177-82 - PubMed
  2. J Clin Invest. 2004 Oct;114(8):1117-27 - PubMed
  3. Oncol Rep. 2003 Sep-Oct;10(5):1337-40 - PubMed
  4. Arch Pathol Lab Med. 2003 Jul;127(7):826-33 - PubMed
  5. Gynecol Oncol. 2007 Feb;104(2):320-5 - PubMed
  6. Nat Rev Cancer. 2003 Jan;3(1):46-54 - PubMed
  7. Surg Oncol. 2003 Aug;12(2):69-90 - PubMed
  8. Nat Med. 1997 Aug;3(8):917-21 - PubMed
  9. Br J Cancer. 2006 Jan 30;94(2):253-8 - PubMed
  10. Cancer Res. 2004 Sep 15;64(18):6359-62 - PubMed
  11. Blood. 2000 Sep 1;96(5):1921-5 - PubMed
  12. J Pathol. 2005 Jun;206(2):123-34 - PubMed
  13. Cancer. 2001 Jun 1;91(11):2026-32 - PubMed
  14. Cancer Res. 2002 Nov 1;62(21):6323-8 - PubMed
  15. J Biol Chem. 2001 May 25;276(21):18563-9 - PubMed
  16. Nature. 1998 Dec 10;396(6711):580-4 - PubMed
  17. Oncol Rep. 2008 Jul;20(1):63-7 - PubMed
  18. J Clin Endocrinol Metab. 2006 Jun;91(6):2201-4 - PubMed
  19. J Oncol. 2011;2011:542358 - PubMed
  20. Arq Bras Endocrinol Metabol. 2007 Jul;51(5):843-51 - PubMed
  21. J Endocrinol Invest. 2008 Feb;31(2):111-8 - PubMed
  22. Cancer Res. 2006 Apr 15;66(8):4263-72 - PubMed
  23. J Lipid Mediat. 1993 Mar-Apr;6(1-3):89-99 - PubMed
  24. Eur J Endocrinol. 2005 Apr;152(4):545-50 - PubMed
  25. J Biol Chem. 2001 Jun 1;276(22):18702-9 - PubMed
  26. Am J Pathol. 2004 Feb;164(2):501-10 - PubMed
  27. Pathol Res Pract. 2008;204(4):241-9 - PubMed
  28. Virchows Arch. 2005 Jul;447(1):12-7 - PubMed
  29. Histopathology. 2003 May;42(5):492-7 - PubMed
  30. Endocr Pathol. 2006 Winter;17(4):377-86 - PubMed

Publication Types